0001493152-23-042022.txt : 20231220 0001493152-23-042022.hdr.sgml : 20231220 20231120124753 ACCESSION NUMBER: 0001493152-23-042022 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20231120 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ensysce Biosciences, Inc. CENTRAL INDEX KEY: 0001716947 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822755287 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 263-4196 MAIL ADDRESS: STREET 1: 7946 IVANHOE AVENUE STREET 2: SUITE 201 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Leisure Acquisition Corp. DATE OF NAME CHANGE: 20170913 CORRESP 1 filename1.htm

 

Ensysce Biosciences, Inc.

7946 Ivanhoe Avenue, Suite 201

La Jolla, California 92037

 

November 20, 2023

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, D.C. 20549

Attention: Jason Drory, Esq.

 

  Re: Ensysce Biosciences, Inc.

Registration Statement on Form S-1

SEC File No. 333-275456

Filed November 9, 2023

Pre-Effective Amendment No. 1 filed November 17, 2023

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, Ensysce Biosciences, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-275456) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 PM, Eastern Time, on November 21, 2023, or as soon thereafter as is practicable, or at such other time thereafter as our counsel, Troutman Pepper Hamilton Sanders LLP, may request by telephone. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Troutman Pepper Hamilton Sanders LLP, by calling Eric D. Kline at (412) 454-5046 or Gregory Rubis at (609) 951-4105.

 

Please direct any questions or comments concerning this request to Eric Kline or Gregory Rubis.

 

 

  ENSYSCE BIOSCIENCES, Inc.
     
  By: /s/ Lynn Kirkpatrick
  Name: Dr. Lynn Kirkpatrick
  Title: President and Chief Executive Officer

 

Cc: Eric D. Kline, Troutman Pepper Hamilton Sanders LLP
  Gregory Rubis, Troutman Pepper Hamilton Sanders LLP